# Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

> **NCT05169268** · — · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 6 (actual)

## Conditions studied

- Schizophrenia and Related Disorders
- Anxiety Depression

## Interventions

- **DRUG:** ARIPiprazole Injection [Abilify]
- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT05169268
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169268, "Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05169268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*